Table 4 Impact of COVID-19 pandemic on clinical research (N = 23)
From: Barriers to symptom management care pathway implementation in pediatric Cancer
n | % | |
|---|---|---|
Obtaining institutional review board approval | ||
Better than usual or no impact | 18 | 78% |
A little more difficult | 5 | 22% |
A lot more difficult or almost impossible | 0 | 0% |
Executing contracts | ||
Better than usual or no impact | 17 | 74% |
A little more difficult | 4 | 17% |
A lot more difficult or almost impossible | 2 | 9% |
Study activation | ||
Better than usual or no impact | 14 | 61% |
A little more difficult | 7 | 30% |
A lot more difficult or almost impossible | 2 | 9% |
Accessing patients in person | ||
Better than usual or no impact | 13 | 57% |
A little more difficult | 8 | 35% |
A lot more difficult or almost impossible | 2 | 9% |
Accessing patients remotely in hospital | ||
Better than usual or no impact | 21 | 91% |
A little more difficult | 2 | 9% |
A lot more difficult or almost impossible | 0 | 0% |
Accessing patients remotely at home | ||
Better than usual or no impact | 19 | 83% |
A little more difficult | 4 | 17% |
A lot more difficult or almost impossible | 0 | 0% |
Accessing hospital systems | ||
Better than usual or no impact | 19 | 83% |
A little more difficult | 4 | 17% |
A lot more difficult or almost impossible | 0 | 0% |
Clinical research associate availability | ||
Better than usual or no impact | 14 | 61% |
A little more difficult | 9 | 39% |
A lot more difficult or almost impossible | 0 | 0% |